TY  - GEN
AU  - Shapiro,Geoffrey I
AU  - Tibes,Raoul
AU  - Gordon,Michael S
AU  - Wong,Bryan Y
AU  - Eder,Joseph Paul
AU  - Borad,Mitesh J
AU  - Mendelson,David S
AU  - Vogelzang,Nicholas J
AU  - Bastos,Bruno R
AU  - Weiss,Glen J
AU  - Fernandez,Cristian
AU  - Sutherland,William
AU  - Sato,Hitoshi
AU  - Pierceall,William E
AU  - Weaver,David
AU  - Slough,Scott
AU  - Wasserman,Ernesto
AU  - Kufe,Donald W
AU  - Von Hoff,Daniel
AU  - Kawabe,Takumi
AU  - Sharma,Sunil
TI  - Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
SN  - 1557-3265
PY  - 2011///1007
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Cisplatin
KW  - Disease Progression
KW  - Female
KW  - G2 Phase
KW  - drug effects
KW  - Genes, cdc
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasms
KW  - drug therapy
KW  - Peptide Fragments
KW  - cdc25 Phosphatases
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-10-2345
ER  -